Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7421214 | 0.82 | FOLH1 (0.48) | FOLH1SIRT2SIRT1SIRT3 | |
| SCHEMBL7045332 | 0.78 | FOLH1 (0.40) | HDAC1HDAC6HDAC2FOLH1MAPT | |
| SCHEMBL7049032 | 0.77 | FOLH1 (0.40) | FOLH1MAPTSIRT2SIRT1SIRT3 | |
| SCHEMBL7046297 | 0.77 | FOLH1 (0.39) | FOLH1FAAHMAPTSIRT2SIRT1 | |
| SCHEMBL7046917 | 0.71 | HDAC1 (0.40) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL24845248 | 0.66 | DPP8 (0.63) | FOLH1MMP2MMP9 | |
| SCHEMBL13471242 | 0.66 | FOLH1 (0.62) | FOLH1MMP2MMP9 | |
| SCHEMBL17250893 | 0.66 | FOLH1 (0.62) | FOLH1MMP2MMP9 | |
| SCHEMBL15177629 | 0.66 | DPP8 (0.63) | FOLH1MMP2MMP9 | |
| SCHEMBL9604544 | 0.66 | FOLH1 (0.62) | FOLH1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | HDAC1 304/4885HDAC6 217/4885HDAC3 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.